Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 21, 2018
Event: Entry into a Material Definitive Agreement regarding an amendment to the Company's senior secured credit agreement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity figures. The document focuses exclusively on a covenant amendment to the Company's debt facility.
- Debt Facility: Senior Secured Credit Agreement (originally dated June 24, 2014).
- Administrative Agent: JPMorgan Chase Bank, N.A.
- Leverage Ratio Adjustment: The maximum permitted leverage ratio was increased from 4.50 to 1.00 to 5.00 to 1.00.
- Duration of Adjustment: Effective until June 29, 2019.
Material Changes
The primary material change is the amendment to the credit agreement to facilitate a specific corporate transaction:
- Permitted Transaction: The amendment permits the sale of the equity of DaVita Medical Holdings, LLC, along with its direct and indirect subsidiaries and associated assets.
- Covenant Relief: To accommodate the transaction, the leverage ratio covenant was temporarily relaxed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard incorporation of the amendment terms by reference. The document notes that the description of the amendment is qualified in its entirety by the complete terms and conditions of the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the specific terms and conditions of the sale of DaVita Medical Holdings, LLC equity in the full text of Exhibit 10.1.
- Confirm the impact of the temporary leverage ratio increase (5.00 to 1.00) on the Company's compliance status post-transaction.
- Monitor the expiration of the leverage ratio adjustment on June 29, 2019, and the Company's ability to return to the 4.50 to 1.00 covenant level.
- Review the full Credit Agreement to understand other covenants that may be affected by the asset sale.